Condition
Stage II Breast Cancer AJCC v6 and v7
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 28 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
28 shownCollecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer DetectionNCT05334069 · 2022-08-18
RECRUITINGMulticenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic TherapyNCT02945579 · 2017-01-20
RECRUITINGTPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and SurgeryNCT04197687 · 2020-02-20
UNKNOWNPatient Reported Outcomes, Smart Pill Bottle and Teleheath for Endocrine Therapy AdherenceNCT04054557 · 2019-07-31
COMPLETEDSCOUT Reflector for Tagging Lymph Nodes for Targeted Removal in Patients With Breast CancerNCT03411070 · 2019-04-07
COMPLETEDGinseng in Decreasing Cancer-Related Fatigue After Treatment in Cancer SurvivorsNCT03407716 · 2019-03-01
COMPLETEDPhase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast SurgeryNCT03317405 · 2018-10-31
ACTIVE_NOT_RECRUITINGIncidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and NeratinibNCT03094052 · 2018-10-09
COMPLETEDThe Effect of Simvastatin on Breast Cancer Cell Growth in Women With Stage I-II Breast CancerNCT03454529 · 2018-03-09
COMPLETEDHypofractionated Radiation Therapy in Preventing Recurrence in Patients With Breast Cancer After SurgeryNCT03324802 · 2018-02-07
COMPLETEDCarboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast CancerNCT02883062 · 2017-08-02
ACTIVE_NOT_RECRUITINGKindness Interventions in Enhancing Well-Being in Breast Cancer SurvivorsNCT03319342 · 2017-07-11
COMPLETEDMagseed Magnetic Marker in Locating Axillary Lymph Nodes in Patients With Breast Cancer Undergoing SurgeryNCT03038152 · 2017-04-11
COMPLETEDMulti-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast CancerNCT03012100 · 2017-03-31
ACTIVE_NOT_RECRUITINGHypofractionated Partial Breast Irradiation in Treating Patients With Early Stage Breast CancerNCT03077841 · 2017-03-06
SUSPENDEDHypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast CancerNCT02912312 · 2017-02-23
ACTIVE_NOT_RECRUITINGTesting MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast CancerNCT02954874 · 2017-01-18
ACTIVE_NOT_RECRUITINGAlternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast CancerNCT02598557 · 2016-12-06
COMPLETEDWomen's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBCNCT02593175 · 2016-11-03
COMPLETEDEnzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast CancerNCT02689427 · 2016-09-22
COMPLETEDBreast Cancer WEight Loss Study (BWEL Study)NCT02750826 · 2016-09-16
ACTIVE_NOT_RECRUITINGElectroacupuncture Therapy in Reducing Chronic Pain in Patients After Breast Cancer TreatmentNCT02754752 · 2016-09-13
ACTIVE_NOT_RECRUITINGCyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After SurgeryNCT02654119 · 2015-12-11
COMPLETEDMolecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot InitiativeNCT02276443 · 2015-11-09
ACTIVE_NOT_RECRUITINGSensorimotor Rehabilitation Program in Improving Quality of Life in Patients With Early Stage Breast CancerNCT03568526 · 2015-07-02
COMPLETEDThe Role of Lifestyle Factors in Breast Cancer-Related OutcomesNCT02079662 · 2013-06-13
ACTIVE_NOT_RECRUITINGHypofractionated Radiation Therapy or Standard Radiation Therapy in Treating Patients With Ductal Breast Carcinoma In Situ or Early Invasive Breast CancerNCT01266642 · 2011-02-08
ACTIVE_NOT_RECRUITINGRadiation Therapy in Treating Patients With Stage 0-II Breast CancerNCT01245712 · 2010-11-15
ACTIVE_NOT_RECRUITINGCommon interventions
Laboratory Biomarker AnalysisOTHER14Questionnaire AdministrationOTHER14Quality-of-Life AssessmentOTHER11PaclitaxelDRUG4Placebo AdministrationOTHER4Biospecimen CollectionPROCEDURE3Hypofractionated Radiation TherapyRADIATION3Radiation TherapyRADIATION3Therapeutic Conventional SurgeryPROCEDURE3TrastuzumabBIOLOGICAL3Axillary Lymph Node DissectionPROCEDURE2Behavioral InterventionBEHAVIORAL2Best PracticeOTHER2CarboplatinDRUG2CyclophosphamideDRUG2Educational InterventionOTHER2Exercise InterventionBEHAVIORAL2Lymph Node BiopsyPROCEDURE2Partial Breast IrradiationRADIATION2SargramostimBIOLOGICAL2Survey AdministrationOTHER2Accelerated Partial Breast IrradiationRADIATION1American GinsengDRUG1AtezolizumabDRUG1Behavioral, Psychological or Informational InterventionOTHER1
Leading sponsors
M.D. Anderson Cancer Center
11
National Cancer Institute (NCI)
4
Academic and Community Cancer Research United
2
Alliance for Clinical Trials in Oncology
2
Jonsson Comprehensive Cancer Center
2
Mayo Clinic
2
Michael Simon
1
Ohio State University Comprehensive Cancer Center
1
Thomas Jefferson University
1
University of California, San Francisco
1
University of Nebraska
1
Trial status mix
COMPLETED13
ACTIVE_NOT_RECRUITING11
RECRUITING2
SUSPENDED1
UNKNOWN1
Phase mix
PHASE214
NA6
PHASE34
EARLY_PHASE12
PHASE11
PHASE41
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.